Capital Impact Advisors’s TherapeuticsMD TXMD Stock Holding History

Capital Impact Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5,258	Closed	-$1.28M	–	128
2018 Q1	$1.28M	Buy	5,258 +1,244	+31%	+$349K	0.53%	105
2017 Q4	$1.21M	Hold	4,014	–	–	0.52%	103
2017 Q3	$1.06M	Buy	4,014 +1,738	+76%	+$502K	0.47%	125
2017 Q2	$600K	Sell	2,276 -872	-28%	-$218K	0.27%	148
2017 Q1	$1.13M	Buy	+3,148	New	+$974K	0.45%	122
2015 Q1	–	Sell	-634	Closed	-$141K	–	301
2014 Q4	$141K	Hold	634	–	–	0.07%	182
2014 Q3	$147	Buy	634 +268	+73%	+$67.5K	﹤0.01%	148
2014 Q2	$81K	Buy	+366	New	+$81.4K	0.06%	217

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Capital Impact Advisors's TXMD Position: Q2 2018 in Review

Capital Impact Advisors sold out of TherapeuticsMD (TXMD) in Q2 2018, closing a stake of 5,258 shares — an estimated $1.28M sold.

Capital Impact Advisors first reported a position in TXMD in Q2 2014 and held it in 8 quarters. The position peaked at $1.28M in Q1 2018. 144 funds tracked by Wall St. Rank hold TXMD as of Q2 2018.

Capital Impact Advisors reported no remaining TherapeuticsMD position as of Q2 2018 after selling out during the quarter.
Capital Impact Advisors sold 5,258 TherapeuticsMD shares in Q2 2018, an estimated $1.28M.
Capital Impact Advisors first reported a position in TherapeuticsMD in Q2 2014 and held it in 8 quarters.
Capital Impact Advisors's TherapeuticsMD position peaked at $1.28M in Q1 2018.
144 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2018.

Based on Capital Impact Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.